On Monday, Capricor Therapeutics Inc (NASDAQ: CAPR) opened higher 4.68% from the last session, before settling in for the closing price of $13.26. Price fluctuations for CAPR have ranged from $3.52 to $23.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 339.72% over the past five years. Company’s average yearly earnings per share was noted -44.41% at the time writing. With a float of $39.96 million, this company’s outstanding shares have now reached $40.33 million.
Let’s look at the performance matrix of the company that is accounted for 102 employees. In terms of profitability, gross margin is 95.71%, operating margin of -154.68%, and the pretax margin is -54151.28%.
Capricor Therapeutics Inc (CAPR) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Capricor Therapeutics Inc is 12.11%, while institutional ownership is 18.56%. The most recent insider transaction that took place on Sep 20 ’24, was worth 14,999,998. In this transaction 10% Owner of this company bought 2,798,507 shares at a rate of $5.36, taking the stock ownership to the 7,090,351 shares.
Capricor Therapeutics Inc (CAPR) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.35 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -44.41% per share during the next fiscal year.
Capricor Therapeutics Inc (NASDAQ: CAPR) Trading Performance Indicators
Check out the current performance indicators for Capricor Therapeutics Inc (CAPR). In the past quarter, the stock posted a quick ratio of 4.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 27.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.06, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -1.01 in one year’s time.
Technical Analysis of Capricor Therapeutics Inc (CAPR)
Capricor Therapeutics Inc (NASDAQ: CAPR) saw its 5-day average volume 1.0 million, a negative change from its year-to-date volume of 1.18 million. As of the previous 9 days, the stock’s Stochastic %D was 21.13%. Additionally, its Average True Range was 1.69.
During the past 100 days, Capricor Therapeutics Inc’s (CAPR) raw stochastic average was set at 52.11%, which indicates a significant increase from 16.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 147.25% in the past 14 days, which was higher than the 142.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.31, while its 200-day Moving Average is $8.85. Nevertheless, the first resistance level for the watch stands at $14.58 in the near term. At $15.29, the stock is likely to face the second major resistance level. The third major resistance level sits at $16.08. If the price goes on to break the first support level at $13.09, it is likely to go to the next support level at $12.30. The third support level lies at $11.59 if the price breaches the second support level.
Capricor Therapeutics Inc (NASDAQ: CAPR) Key Stats
There are currently 45,470K shares outstanding in the company with a market cap of 631.12 million. Presently, the company’s annual sales total 25,180 K according to its annual income of -22,290 K. Last quarter, the company’s sales amounted to 2,260 K and its income totaled -12,560 K.
